Genentech vs ConcertAI

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (72 vs 74)
Genentech logo

Genentech

LeaderLife Sciences & BioTech

Biopharmaceuticals

Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.

AI VisibilityBeta
Overall Score
B72
Category Rank
#17 of 198
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
74
Perplexity
72
Gemini
66

About

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.

Full profile
ConcertAI logo

ConcertAI

LeaderLife Sciences & BioTech

Oncology AI & Real-World Data

ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.

AI VisibilityBeta
Overall Score
B74
Category Rank
#2 of 198
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
69
Gemini
70

About

ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.

Full profile

AI Visibility Head-to-Head

72
Overall Score
74
#17
Category Rank
#2
76
AI Consensus
80
stable
Trend
stable
74
ChatGPT
73
72
Perplexity
69
66
Gemini
70
75
Claude
70
68
Grok
77

Key Details

Category
Biopharmaceuticals
Oncology AI & Real-World Data
Tier
Leader
Leader
Entity Type
company
brand

Capabilities & Ecosystem

Capabilities

Only Genentech
Biopharmaceuticals
Genentech is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.